Caricamento...
Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
BACKGROUND: Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation‐predominant irritable bowel syndrome (IBS‐C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS‐C clinical trials, recommending a composite endpoi...
Salvato in:
| Pubblicato in: | Aliment Pharmacol Ther |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215520/ https://ncbi.nlm.nih.gov/pubmed/27669680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13807 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|